The U.S. Food and Drug Administration has approved FAYUVI (rebisufligene etisparvovec-hopf), the first FDA-approved treatment for pediatric patients with mucopolysaccharidosis type IIIA, better known as Sanfilippo syndrome type A. The September 17 approval adds a new gene-therapy option for a rare inherited disease that progressively damages the brain and nervous system.
According to the FDA, Sanfilippo syndrome type A is caused by a deficiency of sulfamidase, an enzyme needed to break down heparan sulfate inside lysosomes. Without enough of the enzyme, heparan sulfate accumulates throughout the body and brain, contributing to progressive loss of cognitive, language and other developmental abilities.
How the AAV9 Gene Therapy Works
FAYUVI is administered once by intravenous infusion. The therapy uses a modified, non-infectious adeno-associated virus serotype 9, or AAV9, as a delivery vehicle. The vector carries a working copy of the SGSH gene into cells so they can produce sulfamidase and improve the breakdown of heparan sulfate.
This is a different approach from treating individual symptoms as they appear. Gene therapy attempts to address the underlying biological defect by giving cells genetic instructions they are missing. BitcoinVersus.tech has followed other developments in gene-therapy research and human testing, while the broader Technology section tracks how emerging engineering and computing systems move from research into real-world use.
Evidence Behind the Approval
The FDA said the therapy’s effectiveness was evaluated using clinical-study data compared with the expected progression of untreated patients from natural-history data. The agency reported a clinically meaningful benefit in neurodevelopmental outcomes in the studied population. Ultragenyx, the therapy’s developer, said the approval is a standard full approval and that commercial product is expected to be available for shipment to qualified treatment centers within 30 to 60 days.
The approval does not eliminate the need for long-term monitoring. The FDA lists important safety considerations including thrombotic microangiopathy and a potential long-term risk associated with integration of inserted genetic material into the genome. Common adverse reactions reported in more than 5% of treated patients included elevated liver enzymes, nausea and vomiting, fever, decreased appetite, changes in white blood cell and platelet counts, and increased amylase. Patients receive corticosteroid treatment beginning before infusion and continuing afterward.
The FDA granted FAYUVI Orphan Drug, Fast Track and Breakthrough Therapy designations. Its formal approval letter identifies the therapy for neurologic manifestations of MPS IIIA in pediatric patients with preserved neurodevelopmental function.
A High-Cost One-Time Treatment
The scientific milestone also comes with a major access question. Reuters reported that Ultragenyx set a U.S. list price of $3.95 million for the one-time therapy. List price is not necessarily the amount ultimately paid by insurers, government programs or patients, but the figure places FAYUVI among the world’s most expensive medicines and highlights the economic challenge surrounding highly specialized gene therapies.
For biotechnology, the approval is another example of AAV-based gene delivery moving from experimental development into regulated clinical use. The next phase will be measured not only by commercial availability, but by long-term patient outcomes, safety monitoring, access to qualified treatment centers and whether the benefits observed in the development program persist over time.
BitcoinVersus.Tech Editor’s Note:
We volunteer daily to ensure the credibility of the information on this platform is Verifiably True. If you would like to support to help further secure the integrity of our research initiatives, please donate here: 3C9o19EH5HSiwEPyCTmEKzxhNCbo2X6TTb
https://x.com/1BitcoinVersus/status/1937006164555993338
BitcoinVersus.tech is not a financial advisor. This media platform reports on financial subjects purely for informational purposes.
Bitcoin Versus 
Leave a comment